Results 11 to 20 of about 110,851 (248)
GSK-3 inhibitors: preclinical and clinical focus on CNS [PDF]
Frontiers in Molecular Neuroscience, 2011 Inhibiting glycogen synthase kinase-3 (GSK-3) activity via pharmacological intervention has become an important target for treating neurodegenerative and psychiatric disorders.
Hagit eEldar-Finkelman, Ana eMartinez
doaj +4 more sources
Modulation of GSK-3 as a therapeutic strategy on Tau pathologies [PDF]
Frontiers in Molecular Neuroscience, 2011 Glycogen synthase kinase 3 (GSK-3) is ubiquitously expressed and unusually active in resting, non-stimulated cells. In mammals, at least three proteins (, and generated from two different genes, gsk3 and gsk3 are widely expressed at both the
Miguel eMedina +2 more
doaj +8 more sources
GSK-3 inhibitors induce chromosome instability [PDF]
BMC Cell Biology, 2007 Background Several mechanisms operate during mitosis to ensure accurate chromosome segregation. However, during tumour evolution these mechanisms go awry resulting in chromosome instability.
Staples Oliver D +3 more
doaj +4 more sources
Lithium and Therapeutic Targeting of GSK-3. [PDF]
Cells, 2021 Lithium salts have been in the therapeutic toolbox for better or worse since the 19th century, with purported benefit in gout, hangover, insomnia, and early suggestions that lithium improved psychiatric disorders. However, the remarkable effects of lithium reported by John Cade and subsequently by Mogens Schou revolutionized the treatment of bipolar ...
Snitow ME, Bhansali RS, Klein PS.
europepmc +5 more sources
GSK‐3 in Neurodegenerative Diseases [PDF]
International Journal of Alzheimer’s Disease, 2011 Glycogen synthase kinase‐3 (GSK‐3) regulates multiple cellular processes, and its dysregulation is implicated in the pathogenesis of diverse diseases. In this paper we will focus on the dysfunction of GSK‐3 in Alzheimer’s disease and Parkinson’s disease. Specifically, GSK‐3 is known to interact with tau, β‐amyloid (Aβ), and α‐synuclein, and as such may
Lei, P, Ayton, S, Bush, AI, Adlard, PA
openaire +4 more sources
Glycogen synthase kinase-3: a new therapeutic target in mood disorders
Psychiatry and Clinical Psychopharmacology, 2021 Mood disorders, including major depressive disorder and bipolar disorder, are common and largely inadequately treated. Additionally, little is known about their etiologies.
Feyza Aricioglu, Salih Gumru
doaj +1 more source
Regulation of GSK-3 Activity as A Shared Mechanism in Psychiatric Disorders
Psychiatry and Clinical Psychopharmacology, 2021 Glycogen synthase kinase-3 (GSK-3), a member of the serine/threonine kinase family was first identified as an inhibitor of the metabolic enzyme glycogen synthase and is now accepted as a widely influential enzyme responsible for many intracellular ...
Ceren Sahin +2 more
doaj +1 more source
The role of GSK‐3 in synaptic plasticity [PDF]
British Journal of Pharmacology, 2008 Glycogen synthase kinase‐3 (GSK‐3), an important component of the glycogen metabolism pathway, is highly expressed in the CNS. It has been implicated in major neurological disorders including Alzheimer's disease, schizophrenia and bipolar disorders. Despite its central role in these conditions it was not known until recently whether GSK‐3 has neuronal ...
Peineau, Stéphane +6 more
openaire +4 more sources
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
Cells, 2020 Glycogen synthase kinase 3 (GSK-3) is a serine/threonine (S/T) protein kinase. Although GSK-3 originally was identified to have functions in regulation of glycogen synthase, it was subsequently determined to have roles in multiple normal biochemical ...
Przemysław Duda +13 more
doaj +1 more source
Cancer Biology & Therapy, 2022 GSK-3β is a serine/threonine kinase implicated in tumorigenesis and chemotherapy resistance. GSK-3β blockade downregulates the NF-κB pathway, modulates immune cell PD-1 and tumor cell PD-L1 expression, and increases CD8 + T cell and NK cell function.
Andrew Hsu +11 more
doaj +1 more source